Allianz Asset Management
MLYS icon

Allianz Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Allianz Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$593K Sell
21,900
-8,300
-27% -$243K ﹤0.01% 1821
2025
Q4 		$1.1M Sell
30,200
-3,500
-10% -$140K ﹤0.01% 1690
2025
Q3 		$1.28M Buy
33,700
+21,400
+174% +$463K ﹤0.01% 1656
2025
Q2 		$166K Buy
+12,300
New +$178K ﹤0.01% 1953

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Allianz Asset Management's MLYS Position: Q1 2026 in Review

Allianz Asset Management reduced its Mineralys Therapeutics (MLYS) stake by 27% in Q1 2026, selling an estimated $243K and leaving 21,900 shares worth $593K. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

Allianz Asset Management first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.28M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Allianz Asset Management held 21,900 shares of Mineralys Therapeutics worth $593K as of Q1 2026.
  • Allianz Asset Management sold 8,300 Mineralys Therapeutics shares in Q1 2026, an estimated $243K.
  • Mineralys Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1821 holding.
  • Allianz Asset Management first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Allianz Asset Management's Mineralys Therapeutics position peaked at $1.28M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.